Skip to main content

Navigation group

Type at least 3 characters
1,333 articles

Articles

Perspective

Published on 28 Jun 2022

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide

in Neuro-Oncology and Neurosurgical Oncology

  • Daniela A. Bota
  • Thomas H. Taylor
  • Naomi Lomeli
  • Xiao-Tang Kong
  • Beverly D. Fu
  • Axel H. Schönthal
  • Samuel Singer
  • Deborah T. Blumenthal
  • Frank M. Senecal
  • Helena Linardou
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
Frontiers in Oncology
doi 10.3389/fonc.2022.934638
  • 6,774 views
  • 4 citations